Source comparison
Tesamorelin Protocol: Dosing Comparison
Daily Dose 2mg subcutaneous once daily 2–4 IU subcutaneous daily (lipodystrophy context) N/A Tesamorelin preserves endogenous pulsatility; exogenous GH suppresses natural secretion Administration Timing Fasting state (morning preferred) Evening (mimics nocturn
This comparison does not assign a generated winner or score.
- Daily Dose
- 2mg subcutaneous once daily
- 2–4 IU subcutaneous daily (lipodystrophy context)
- N/A
- Tesamorelin preserves endogenous pulsatility; exogenous GH suppresses natural secretion
- Administration Timing
- Fasting state (morning preferred)
- Evening (mimics nocturnal peak)
- Fasting maximises pituitary response to GHRH. Non-negotiable for tesamorelin
- VAT Reduction (26 weeks)
- 15.2% mean reduction (Phase 3 data)
- 10–12% (observational, not controlled trials)
- 3–5% (metabolic syndrome cohorts)
- Tesamorelin shows largest effect size in controlled lipodystrophy trials
- Glucose Impact
- Transient elevation in 8–10%; resolves with VAT loss
- Persistent insulin resistance common
- Improves with caloric deficit
- Tesamorelin risk is front-loaded and self-limiting; GH risk is cumulative
- Reconstitution Stability
- Use within 3 hours (no preservative)
- 14–28 days refrigerated (with bacteriostatic water)
- Tesamorelin requires same-day reconstitution. No multi-dose storage option
- Regulatory Status
- FDA-approved for HIV lipodystrophy (Egrifta)
- Off-label for lipodystrophy; approved for GH deficiency
- Tesamorelin is the only FDA-approved pharmacotherapy specifically for this indication